Viral lesions of the mouth in HIV-infected patients.
Viral lesions of the mouth in patients with HIV infection are common and these diseases any be a marker for HIV and disease progression. We review the spectrum of oral viral manifestations and discuss treatment modalities. The most common Epstein-Barr virus (EBV)-induced disorder in HIV-infected patients is oral hairy leukoplakia. EBV-related oral B-cell and T-cell lymphoma in AIDS patients has been described repeatedly. Herpes virus type 1 and rarely type 2 may lead to painful and resistant oral ulcers, and systemic treatment with acyclovir, valaciclovir or famciclovir is indicated. In acyclovir-resistant cases foscarnet is the treatment of choice. In recent years it has been documented that Kaposi's sarcoma, which often affects oral mucosa, is probably induced by herpesvirus type 8. Cytomegalovirus was found in 53% of cases with herpesviridae-induced mucosal ulcers as the only ulcerogenic viral agent in AIDS patients. In severe cytomegalovirus infection treatment with ganciclovir is helpful. Viral warts induced by different HPV may occur in the mouth. Several physical treatment modalities are possible in the oral mucosa. In AIDS patients mollusca contagiosa may occur as large and atypical lesions in the face and lips and rarely in the oral cavity. Cryotherapy is a bloodless treatment in such patients.
Itin
P H
PH
Department of Dermatology, University of Basel, Switzerland.
Lautenschlager
S
S
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis*; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000188:drug therapy; D018450:Disease Progression; D000077595:Famciclovir; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D006566:Herpesviridae Infections / Q000175:diagnosis; D018259:Herpesvirus 1, Human; D018258:Herpesvirus 2, Human; D004854:Herpesvirus 4, Human; D019288:Herpesvirus 8, Human; D006801:Humans; D017733:Leukoplakia, Hairy / Q000175:diagnosis; D016393:Lymphoma, B-Cell / Q000821:virology; D016399:Lymphoma, T-Cell / Q000821:virology; D008976:Molluscum Contagiosum / Q000175:diagnosis; D009059:Mouth Diseases / Q000821:virology*; D009062:Mouth Neoplasms / Q000821:virology; D019226:Oral Ulcer / Q000188:drug therapy / Q000821:virology; D011355:Prodrugs / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000821:virology; D013283:Stomatitis, Herpetic / Q000175:diagnosis / Q000188:drug therapy; D014412:Tumor Virus Infections / Q000175:diagnosis; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014777:Virus Diseases / Q000175:diagnosis*; D014860:Warts / Q000175:diagnosis
D019380:Anti-HIV Agents; D011355:Prodrugs; D017245:Foscarnet; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D015774:Ganciclovir; D000077595:Famciclovir; D000212:Acyclovir